CN1676156A - 一种治疗类风湿性关节炎的中药组合物 - Google Patents
一种治疗类风湿性关节炎的中药组合物 Download PDFInfo
- Publication number
- CN1676156A CN1676156A CNA200410029884XA CN200410029884A CN1676156A CN 1676156 A CN1676156 A CN 1676156A CN A200410029884X A CNA200410029884X A CN A200410029884XA CN 200410029884 A CN200410029884 A CN 200410029884A CN 1676156 A CN1676156 A CN 1676156A
- Authority
- CN
- China
- Prior art keywords
- weight
- weight portions
- weight portion
- group
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 239000000203 mixture Substances 0.000 title claims description 11
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims description 9
- 208000025747 Rheumatic disease Diseases 0.000 title 1
- 230000000552 rheumatic effect Effects 0.000 title 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 5
- 235000008434 ginseng Nutrition 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims description 62
- 239000007788 liquid Substances 0.000 claims description 18
- 239000003826 tablet Substances 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 5
- 241000208340 Araliaceae Species 0.000 claims description 4
- 241001251068 Formica fusca Species 0.000 claims description 4
- 241000131808 Scolopendra Species 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- -1 suspensoid Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 239000002131 composite material Substances 0.000 abstract 2
- 241000173529 Aconitum napellus Species 0.000 abstract 1
- 244000077995 Coix lacryma jobi Species 0.000 abstract 1
- 241000521581 Millettia Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 229940023019 aconite Drugs 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 39
- 210000002683 foot Anatomy 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 206010061218 Inflammation Diseases 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 241000053227 Themus Species 0.000 description 13
- 230000037396 body weight Effects 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 230000004054 inflammatory process Effects 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 11
- 230000008961 swelling Effects 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 208000009386 Experimental Arthritis Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 7
- 102000002322 Egg Proteins Human genes 0.000 description 7
- 108010000912 Egg Proteins Proteins 0.000 description 7
- 241000287828 Gallus gallus Species 0.000 description 7
- 206010018691 Granuloma Diseases 0.000 description 7
- 229960000583 acetic acid Drugs 0.000 description 7
- 206010003246 arthritis Diseases 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 210000004681 ovum Anatomy 0.000 description 7
- 101100438957 Mus musculus Cd8a gene Proteins 0.000 description 6
- 230000004856 capillary permeability Effects 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- 210000000683 abdominal cavity Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 231100000915 pathological change Toxicity 0.000 description 5
- 230000036285 pathological change Effects 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 231100000862 numbness Toxicity 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 240000001624 Espostoa lanata Species 0.000 description 3
- 235000009161 Espostoa lanata Nutrition 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000003024 peritoneal macrophage Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 2
- 108700031361 Brachyury Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 125000002324 prednisone group Chemical group 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- CJDPJFRMHVXWPT-UHFFFAOYSA-N barium sulfide Chemical compound [S-2].[Ba+2] CJDPJFRMHVXWPT-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 125000000017 cortisol group Chemical group 0.000 description 1
- 125000000853 cresyl group Chemical group C1(=CC=C(C=C1)C)* 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003118 prednisones Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 剂量(g/kg) | 鼠数 | 肿胀度(mm, X±S) | ||
15min | 30min | 4h | |||
对照组本发明胶囊剂组本发明胶囊剂组本发明胶囊剂组雷公藤组 | 31.50.75甲素66ug | 1010101010 | 1.7±0.21.0±0.2***1.3±0.2***1.4±0.4*1.0±0.2*** | 2.1±0.41.5±0.3***1.7±0.2**1.7±0.3**1.2±0.4*** | 1.6±0.21.0±0.2***1.2±0.2***1.3±0.2***1.0±0.2*** |
组别 | 剂量(g/kg) | 鼠数 | 肿胀度(mm, X±S) | ||
12h | 24h | 72h | |||
对照组本发明胶囊剂组本发明胶囊剂组本发明胶囊剂组雷公藤组 | 31.50.75甲素66ug | 1010101010 | 2.1±0.41.3±0.3***1.6±0.3***1.7±0.3**1.3±0.3*** | 2.1±0.41.6±0.2***1.8±0.2***2.0±0.3***1.6±0.2*** | 2.3±0.41.4±0.3***1.7±0.3***1.8±0.3***1.4±0.3*** |
组别 | 剂量(g/kg) | 鼠数 | 给佐剂后左足跖肿胀度(ml) | |||
8日 | 13日 | 18日 | 23日 | |||
对照组本发明胶囊剂组本发明胶囊剂组本发明胶囊剂组雷公藤组 | 31.50.75甲素66ug | 88888 | 0.34±0.060.28±0.05**0.30±0.06*0.32±0.05*0.28±0.04** | 0.41±0.050.30±0.05***0.33±0.06**0.37±0.05*0.3l±0.05*** | 0.42±0.050.30±0.06***0.33±0.04***0.37±0.04**0.31±0.05*** | 0.34±0.050.27±0.05**0.29±0.04**0.32±0.03*0.27±0.05** |
组别 | 剂量(g/kg) | 鼠数 | 给佐剂后左足跖肿胀度(ml) | ||
15日 | 20日 | 25日 | |||
对照组本发明胶囊剂组本发明胶囊剂组本发明胶囊剂组雷公藤组 | 31.50.75甲素66ug | 88888 | 0.24±0.060.15±0.04***0.17±0.04**0.20±0.03*0.15±0.03*** | 0.26±0.070.14±0.04***0.18±0.06**0.20±0.03**0.15±0.03*** | 0.2l±0.050.12±0.03***0.15±0.03***0.17±0.04*0.12±0.02*** |
组别 | 剂量(g/kg) | 鼠数 | 给佐剂后体重(g, X±S) | ||
0日 | 15日 | 25日 | |||
对照组本发明胶囊剂组本发明胶囊剂组本发明胶囊剂组雷公藤组 | 31.50.75甲素66ug | 88888 | 184±7183±7186±6185±7185±7 | 190±8199±9198±9195±7200±7** | 194±9209±9***207±9**202±7208±7*** |
组别 | 剂量(g/kg) | 给药途径 | 鼠数 | 腹腔透出染料吸收度值 X±S | 抑制率(%) | P |
对照组本发明胶囊剂组本发明胶囊剂组本发明胶囊剂组氢化可的松组 | 31.50.750.02 | igigigim | 108797 | 0.172±0.0910.101±0.0210.116±0.0640.110±0.0230.153±0.054 | 41.332.636.011.0 | <0.05>0.05>0.05>0.05 |
组别 | 剂量(g/kg) | 鼠数 | CMC囊中白细胞数(109/L) | |
3小时 | 7.5小时 | |||
对照组本发明胶囊剂组本发明胶囊剂组雷公藤组 | 42甲素66ug | 6666 | 11.4±5.68.7±1.95.6±2.1**7.8±2.0 | 18.8±9.012.8±7.512.2±3.313.3±2.8 |
组别 | 剂量(g/kg) | 鼠数 | 肉芽肿(mg) | P |
对照组本发明胶囊剂组本发明胶囊剂组本发明胶囊剂组雷公藤组 | 31.50.75甲素66ug | 1010101010 | 99.8±16.581.0±5.484.5±5.398.3±16.182.2±11.0 | <0.01<0.05>0.05<0.05 |
组别 | 剂量(g/kg) | 鼠数 | 反应时(秒) | 变化率(%) | P |
对照组本发明胶囊剂组本发明胶囊剂组本发明胶囊剂组雷公藤组 | 31.50.75甲素66ug | 1010101010 | 22.1±5.864.1±7.946.5±8.238.6±6.865.8±7.5 | 100290210175298 | <0.01<0.01<0.01<0.01<0.01 |
组别 | 剂量(g/kg) | 鼠数 | 扭体次数( X±SD) | 抑制率(%) | P |
对照组本发明胶囊剂组本发明胶囊剂组本发明胶囊剂组雷公藤组 | 31.50.75甲素66ug | 1010101010 | 48.4±8.811.3±4.518.1±6.722.7±7.610.6±4.5 | 76.662.653.178.1 | <0.01<0.01<0.01<0.01 |
组别 | 剂量(g/kg) | 鼠数 | OD值 |
对照组模型组本发明胶囊剂组本发明胶囊剂组强的松组 | 52.55mg | 66666 | 0.24±0.01***0.87±0.030.48±0.03***0.54±0.01***0.34±0.02*** |
组别 | 剂量(g/kg) | 鼠数 | 细胞数(%) | L3T4 +/Lyt-2+ | |
L3T4 + | Lyt-2+ | ||||
对照组模型组本发明胶囊剂组本发明胶囊剂组本发明胶囊剂组强的松组 | 52.51.255mg | 666666 | 54.1±1.964.9±4.662.7±3.767.5±4.269.7±3.759.6±7.5 | 45.6±2.740.3±2.147.7±5.445.4±3.040.0±2.556.2±3.8*** | 1.19±0.07***1.56±0.101.34±0.28**1.49±0.141.53±0.101.21±0.14*** |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200410029884XA CN1273178C (zh) | 2004-03-31 | 2004-03-31 | 一种治疗类风湿性关节炎的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200410029884XA CN1273178C (zh) | 2004-03-31 | 2004-03-31 | 一种治疗类风湿性关节炎的中药组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1676156A true CN1676156A (zh) | 2005-10-05 |
CN1273178C CN1273178C (zh) | 2006-09-06 |
Family
ID=35049007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200410029884XA Expired - Lifetime CN1273178C (zh) | 2004-03-31 | 2004-03-31 | 一种治疗类风湿性关节炎的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1273178C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104248676A (zh) * | 2014-09-30 | 2014-12-31 | 韦振良 | 治疗风湿的药物及其制备方法 |
CN104547086A (zh) * | 2015-01-30 | 2015-04-29 | 王桂霞 | 一种治疗类风湿性关节炎的中药组合物 |
CN101698072B (zh) * | 2009-10-30 | 2015-05-13 | 浙江医药高等专科学校 | 一种治疗风湿关节炎的中药组合物及其制备方法 |
CN107496614A (zh) * | 2017-08-17 | 2017-12-22 | 成都新柯力化工科技有限公司 | 一种用于骨修复和镇痛的中药贴及其制备方法 |
-
2004
- 2004-03-31 CN CNB200410029884XA patent/CN1273178C/zh not_active Expired - Lifetime
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101698072B (zh) * | 2009-10-30 | 2015-05-13 | 浙江医药高等专科学校 | 一种治疗风湿关节炎的中药组合物及其制备方法 |
CN104248676A (zh) * | 2014-09-30 | 2014-12-31 | 韦振良 | 治疗风湿的药物及其制备方法 |
CN104547086A (zh) * | 2015-01-30 | 2015-04-29 | 王桂霞 | 一种治疗类风湿性关节炎的中药组合物 |
CN107496614A (zh) * | 2017-08-17 | 2017-12-22 | 成都新柯力化工科技有限公司 | 一种用于骨修复和镇痛的中药贴及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1273178C (zh) | 2006-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7662412B2 (en) | Traditional Chinese medicine composition to treat rheumatoid arthritis and preparation method thereof | |
CN1836720A (zh) | 一种治疗关节炎或痛风的中药组合物及其制备方法 | |
CN100355450C (zh) | 秦川通痹片 | |
CN105535505A (zh) | 一种制备治疗肝胆结石的药物组合物的方法 | |
CN1273178C (zh) | 一种治疗类风湿性关节炎的中药组合物 | |
CN1259955C (zh) | 一种治疗妇女更年期综合征的中药制剂 | |
CN101066417A (zh) | 孕康口服液在制备治疗妇女月经不调药物中的用途 | |
CN1840160A (zh) | 抗骨质增生粉 | |
CN103340940A (zh) | 一种治疗便秘的藏药及其制备方法 | |
CN101066309A (zh) | 一种抗内毒素血症的中药组合物及其制备方法 | |
CN100363033C (zh) | 一种治疗风寒湿痹症疼痛的药物及其制备方法 | |
CN1308032C (zh) | 一种治疗功能失调性子宫出血的药物组合物及其制备方法 | |
CN1712055A (zh) | 一种治疗泌尿系结石的中药制剂(溶石胶囊) | |
CN1264540C (zh) | 治疗急性黄疸肝炎的中药及其制备方法 | |
CN102274433A (zh) | 一种治疗慢性盆腔炎的中药及其制备方法 | |
CN1269501C (zh) | 一种治疗慢性结肠炎的药物及制备方法 | |
CN1294948C (zh) | 一种益气健脾滋补肝肾的药物及其制备方法 | |
CN1329075C (zh) | 一种治疗痛症的中成药颗粒剂的制备方法 | |
CN1270755C (zh) | 一种治疗风湿类风湿性关节炎的药物组合物 | |
CN104147268B (zh) | 一种治疗肝胆结石的中药组合物及其制剂 | |
CN102727730B (zh) | 治疗男性不育的复方中药制剂及其制备方法 | |
CN108671195A (zh) | 一种用于治疗关节炎的中药组合物及制剂 | |
CN1586512A (zh) | 一种治疗肝病的药 | |
CN100340267C (zh) | 一种治疗脂肪肝的中药制剂 | |
CN1270763C (zh) | 化瘀固精制剂及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHENGDE JINGFUKANG PHARMACY GROUP CO.,LTD. Free format text: FORMER OWNER: GUO LAIWANG Effective date: 20091030 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20091030 Address after: Hi tech Industrial Development Zone, Chengde, Hebei Patentee after: Chengde Jingfukang Pharmaceutical Group Co.,Ltd. Address before: Room 206, guest house, provincial science and Technology Department, 366 Yingze Avenue, Shanxi, Taiyuan Patentee before: Guo Laiwang |
|
C56 | Change in the name or address of the patentee |
Owner name: JINGFUKANG PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: JINGFUKANG PHARMACEUTICAL GROUP CO., LTD., CHENGDE |
|
CP01 | Change in the name or title of a patent holder |
Address after: 067000 hi tech Industrial Development Zone, Hebei, Chengde Patentee after: JINGFUKANG PHARMACEUTICAL GROUP Co.,Ltd. Address before: 067000 hi tech Industrial Development Zone, Hebei, Chengde Patentee before: Chengde Jingfukang Pharmaceutical Group Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20060906 |
|
CX01 | Expiry of patent term |